CDR 641L
Alternative Names: CDR-641LLatest Information Update: 17 Sep 2021
At a glance
- Originator Hannover Medical School
- Developer Cardior Pharmaceuticals
- Class Heart failure therapies; Oligonucleotides
- Mechanism of Action Long noncoding RNA modulators; MicroRNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hypertrophic cardiomyopathy
Most Recent Events
- 17 Sep 2021 Cardior therapeutics in-licenses four patents covering the use of certain miRNAs from Bayerische Patentallianz (Cardior therapeutics pipeline, September 2021)
- 03 Sep 2021 Preclinical trials in Hypertrophic cardiomyopathy in Germany (unspecified route) (Cardior Pharmaceuticals pipeline, September 2021)
- 01 Nov 2018 Cardior Pharmaceuticals has patent protection for use of certain miRNAs